



BLUE JET HEALTHCARE LIMITED

REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705

T : 022- 41840550 / 40037603

F : +91 22 27814204

E : sales@bluejethealthcare.com

CIN NO. : L99999MH1968PLC014154

November 4, 2025

To,

The Manager Listing Department BSE Limited Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
---	---

Sub.: Outcome of Board Meeting held today i.e, Tuesday, November 4, 2025.

Dear Sir / Ma'am,

In terms of Regulation 30 and Regulation 33 read with Schedule III and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Board of Directors of the Company at their meeting held today viz. Tuesday, November 4, 2025, *inter-alia*, has approved the following: -

- Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2025. A signed copy of the Unaudited Standalone Financial Results along with the Limited Review Report thereon is enclosed herewith.

The meeting commenced at 12:06 P.M. and concluded at 12:25 P.M.

Kindly take the same on your record.

Thanking you,
Yours faithfully,

For Blue Jet Healthcare Limited

Sweta Poddar
Company Secretary & Compliance Officer
Mem. No. F12287

Unit I
3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, Tel.: 91 251 2280283 Fax : +91 251 2280567
Unit II
Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambernath (W) 421501. Tel. : +91 8956363877/8956363878
Unit III
K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, Tel.: + 91 22 2207 5307 / 6192 / 1691 Fax : +91 22 2207 0294

Email : info@bluejethealthcare.com / Website : www.bluejethealthcare.com

kkc & associates llp

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Independent Auditor's Review Report on unaudited financial results for the quarter ended 30 September 2025 and year to date results for the period from 01 April 2025 to 30 September 2025 of Blue Jet Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Blue Jet Healthcare Limited

Introduction

1. We have reviewed the accompanying statement of unaudited financial results of Blue Jet Healthcare Limited ('the Company') for the quarter ended 30 September 2025 and year to date results for the period from 01 April 2025 to 30 September 2025 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KKC & Associates LLP

Chartered Accountants

(formerly Khimji Kunverji & Co LLP)

Firm Registration Number: 105146W/W100621

Kamlesh R Jagetia

Partner

ICAI Membership No: 139585

UDIN: 25139585BMOWCW2677

Place: Navi Mumbai

Date: 04 November 2025



Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India

T: +91 22 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267

Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India

BLUE JET HEALTHCARE LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS AND SIX MONTHS ENDED 30-09-2025

₹ in million

Particulars	Three Months Ended			Six Months Ended		Year Ended
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from Operations	1,654.81	3,547.58	2,082.60	5,202.39	3,711.58	10,299.85
2 Other Income	242.71	82.54	120.74	325.25	207.90	462.56
3 Total Income (1+2)	1,897.52	3,630.12	2,203.34	5,527.64	3,919.48	10,762.41
4 Expenses						
Cost of Materials Consumed	1,084.24	1,078.90	1,146.25	2,163.14	2,055.20	5,402.45
Changes [Decrease /(Increase)] in Inventories of Finished goods and Work-in-Progress	(505.58)	750.07	(251.10)	244.49	(421.92)	(790.24)
Employee Benefits Expense	185.54	174.26	153.99	359.80	301.80	609.97
Finance Costs	46.27	6.90	0.21	53.17	0.48	0.98
Depreciation and Amortisation Expense	58.66	56.98	46.15	115.64	80.97	177.89
Other Expenses	341.12	334.41	338.60	675.53	639.01	1,300.37
Total Expenses	1,210.25	2,401.52	1,434.10	3,611.77	2,655.54	6,701.42
5 Profit before Tax (3-4)	687.27	1,228.60	769.24	1,915.87	1,263.94	4,060.99
6 Tax Expense:						
Current Tax	179.10	298.00	177.50	477.10	275.00	965.00
Short/ (Excess) Tax Provision related to prior years	-	-	-	-	-	2.75
Deferred Tax (credit)/ charge	(13.19)	18.90	8.25	5.70	27.67	41.21
Total Tax Expense	165.91	316.90	185.75	482.80	302.67	1,008.96
7 Profit for the period/ year (5-6)	521.36	911.70	583.49	1,433.07	961.27	3,052.03
8 Other Comprehensive Income						
(i) Items that will not be reclassified to profit or loss	1.48	-	-	1.48	-	0.42
(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.37)	-	-	(0.37)	-	(0.10)
Other Comprehensive Income for the period/ year	1.11	-	-	1.11	-	0.32
9 Total Comprehensive Income for the period/ year (7 + 8)	522.47	911.70	583.49	1,434.18	961.27	3,052.35
10 Paid-up Equity Share Capital (Face Value ₹ 2 per share)	346.93	346.93	346.93	346.93	346.93	346.93
11 Other Equity						10,984.18
12 Earnings per Share (EPS) of Face value ₹ 2/- each*						
(a) Basic - (₹)	3.01	5.26	3.36	8.26	5.54	17.59
(b) Diluted - (₹)	3.01	5.26	3.36	8.26	5.54	17.59

*EPS are not annualised for interim periods



Notes:

1

STATEMENT OF ASSETS AND LIABILITIES

₹ in million

	Particulars	As at	As at
		30-09-2025	31-03-2025
		(Unaudited)	(Audited)
A.	ASSETS		
1	Non Current Assets		
	Property Plant and Equipment	2,598.73	2,596.42
	Intangible Assets	3.33	2.33
	Capital Work in Progress	1,587.62	888.84
	Intangible assets under development	10.61	2.80
	Right of Use Assets	420.29	404.12
	Financial Assets		
	Other Financial Assets	59.88	55.14
	Other Non-Current Assets	693.55	166.19
	Total Non-Current Assets	5,374.02	4,115.84
2	Current Assets		
	Inventories	1,967.90	2,639.24
	Financial Assets		
	Investments (Current)	2,103.96	1,866.92
	Trade Receivables	3,118.27	3,495.33
	Cash and Cash Equivalents	669.98	329.79
	Other Balances with Banks	1,339.31	868.09
	Other Current Financial Assets	62.43	86.66
	Other Current Assets	638.73	773.44
	Total Current Assets	9,900.58	10,059.47
	TOTAL ASSETS	15,274.60	14,175.31
B.	EQUITY AND LIABILITIES		
1	EQUITY		
	Equity Share Capital	346.93	346.93
	Other Equity	12,210.24	10,984.18
	LIABILITIES		
2	Non-Current Liabilities		
	Financial Liabilities		
	Lease Liability	173.04	165.26
	Provisions	54.58	46.96
	Deferred Tax Liabilities (Net)	78.98	72.91
	Total Non-Current Liabilities	12,863.77	11,616.24
3	Current Liabilities		
	Financial Liabilities		
	Lease Liability	33.25	34.60
	Trade Payables		
	Total outstanding dues of Micro, Small and Medium Enterprises	24.34	18.87
	Total outstanding dues to other than Micro, Small and Medium enterprises.	382.15	871.66
	Other Current Financial Liabilities	648.53	284.03
	Current Tax Liabilities (Net)	1,270.20	1,317.90
	Other Current Liabilities	34.72	18.84
	Provisions	17.64	13.17
	Total Current Liabilities	2,410.83	2,559.07
	TOTAL EQUITY AND LIABILITIES	15,274.60	14,175.31



STATEMENT OF CASH FLOWS

₹ in million

Particulars	Six months ended	Six months ended
	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)
A. Cash Flow from Operating Activities:		
Profit Before tax	1,915.87	1,263.94
Adjustments for:		
Depreciation and Amortisation	115.64	80.97
(Gain)/Loss on Fair Valuation of Investments	(40.69)	(87.37)
Provision for Employee Benefits	15.43	11.00
Provision for Bad Debts/ Bad debts Written off	0.43	(0.69)
Excess provision written back (net)	-	(0.09)
Interest Income	(43.86)	(22.75)
Preference Dividend	0.01	0.01
Finance Costs	53.16	0.47
Unrealised Foreign Exchange (Gain) / Loss	(60.46)	(28.40)
Amortization of Deferred Lease Expense	0.21	0.20
(Profit) / Loss on Sale / Retirement of Property, Plant and Equipment (net)	-	(2.51)
Provision for doubtful advances/ receivables	-	1.56
Profit on Sale of Current Investments (net)	(44.25)	(8.94)
Operating profit before working capital changes	1,911.49	1,207.40
Movements in working capital:		
(Increase)/ Decrease in Trade payables and other Liabilities	(433.81)	387.14
Decrease/ (Increase) in Trade receivables	483.44	(320.21)
Decrease/ (Increase) in Inventories	671.34	(481.91)
(Increase)/ Decrease in Financial and Other Assets	(35.79)	193.03
Cash generated from Operations	685.18	(221.95)
Taxes paid (net of refunds)	(524.80)	(364.87)
Net Cash generated from Operating Activities (A)	2,071.87	620.58
B Cash Flow from Investing Activities:		
Purchase of Property, Plant and Equipment and Intangible assets	(1,254.65)	(452.19)
Sale of Property, Plant and Equipment	-	3.82
Redemption/ (Investment) in Fixed Deposits (net)	(282.50)	50.00
Purchase of Investments	(3,060.05)	(599.31)
Sale of Investments	2,907.96	266.15
Interest received	42.92	5.52
Net Cash used in Investing Activities (B)	(1,646.32)	(726.01)
C Cash Flow from Financing Activities:		
Repayment of Principal towards Lease Liability	(32.20)	(5.34)
Interest Paid on Lease Liability	(6.24)	(0.47)
Preference Dividend Paid	-	(0.01)
Interest Paid	(46.92)	-
Net Cash used in Financing Activities (C)	(85.36)	(5.82)
Net Increase/ (Decrease) in Cash and Cash Equivalents (A + B + C)	340.19	(111.24)
Cash and Cash Equivalents at the beginning of the period	329.79	409.54
Cash and Cash Equivalents at the end of the period	669.98	298.30



- 3 The above financial results of the Company for the three months and six months ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 04, 2025. Further, the above financial results have been reviewed by the Statutory Auditor of the Company.
- 4 The company is engaged in manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products.
- 5 The Company does not have any subsidiaries, associates, or joint ventures as on September 30, 2025. Consequently, the preparation of consolidated financial statements is not applicable.

For and on behalf of Board of Directors

Shiven Arora

Managing Director

Navi Mumbai

Date: November 04, 2025

